Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
Healthcare
$9.12 +0.00%
+$0.00 today
- Market cap
- $605.45M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
52W Low $8.48High $24.25
Volume 0.84M
Average 0.54M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$106.83M
FY 2025 · Annual
Investing Cash Flow
-$318.45M
FY 2025 · Annual
Financing Cash Flow
$32.26M
FY 2025 · Annual
-90.3% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Depreciation & Amortization | 10K | 19K | 56K | 406K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 810K | 1.9M | 7.4M | 15.01M |
| Change in Working Capital | 4.95M | (9.62M) | (14.13M) | 14.81M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 2.64M | 0 |
| Other Working Capital | 4.95M | (9.62M) | (16.77M) | 14.81M |
| Other Non-Cash Items | 810K | 14.06M | (77K) | 895K |
| Operating Cash Flow | (32.08M) | (45.63M) | (74.75M) | (106.83M) |
| Capital Expenditures | (192K) | (586K) | (71K) | (280K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (318.17M) |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 62K | 0 |
| Investing Cash Flow | (192K) | (586K) | (9K) | (318.45M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 332.43M | 32.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 160K | 149K | 1.6M | 0 |
| Financing Cash Flow | 31.7M | 272.5M | 334.03M | 32.26M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (573K) | 226.28M | 259.27M | (393.03M) |
| Free Cash Flow | (32.27M) | (46.21M) | (74.82M) | (107.11M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$137.9M
+ D&A$406.0K
+ Stock-Based Comp$15.0M
+ Deferred Tax$0
+ Working Capital$14.8M
+ Other Non-Cash$895.0K
= Operating Cash Flow-$106.8M
- Capex-$280.0K
= Free Cash Flow-$107.1M
Analysis
FY2025 free cash flow is -$107.1M. FCF conversion is 77.6% of net income. Operating cash flow was -$106.8M, with capex of -$280.0K. The largest bridge item is Stock-Based Comp at $15.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 10, 2026 |
Does BCAX generate free cash flow?
Bicara Therapeutics Inc. Common Stock (BCAX) generated -$107.11M of free cash flow in fiscal 2025.
How much operating cash flow does BCAX produce?
Operating cash flow was -$106.83M, before capital expenditures of $280,000.00.
Continue the stock analysis
Jump to another research area for this company.